Weight Loss Drugs Show Promise for Young People, Sparking Debate Over Use
A recent study indicates that weight loss drugs, like GLP-1 receptor agonists (similar to ozempic), are effective in helping children and teenagers lose weight and improve metabolic health. However, the findings are fueling a broader discussion about the appropriate use of these medications in young populations, including access, duration of treatment, and potential long-term effects.
The study highlighted notable weight loss and improvements in health markers among young participants. Independent experts suggest the effects of these drugs could be even more pronounced in children and adolescents compared to adults.Currently, studies have largely focused on individuals aged 12 and older, perhaps making some doctors hesitant to prescribe to younger children, tho trials are now underway to assess efficacy in children as young as six.
dr. Julian Hamilton-Shield, a professor of diabetes and metabolic endocrinology at the university of Bristol, believes offering GLP-1 agonists is “justified” for severely obese children and teenagers with related health complications, such as obstructive sleep apnoea requiring ventilation. he emphasized the potential for significant improvements in quality of life,self-esteem,and overall wellbeing for these patients. Though, he stresses that treatment should occur within specialist clinics offering comprehensive support, including mental health services, dieticians, and nurses, to facilitate sustained lifestyle changes and prevent weight regain after discontinuing medication – a common challenge observed in adult patients.
The rising rates of childhood obesity are driving the urgency of this discussion. UNICEF data reveals that nearly one in ten children globally are obese, increasing their risk of developing lifelong health problems like diabetes, high blood pressure, heart disease, and fatty liver disease. Severe obesity can also significantly shorten life expectancy.
Dr. Mohamad Maghnie of the Giannina Gaslini Institute in Italy suggests early intervention with these drugs could be particularly beneficial, offering “a window of opportunity” to improve young people’s health.
Despite the promising results, researchers acknowledge outstanding questions regarding the long-term safety of these drugs in young people. Concerns remain about potential impacts on growth, puberty, bone health, and psychosocial development. The cost of treatment and the severity of potential side effects also require careful consideration. Researchers suggest GLP-1s may be best utilized as a temporary tool to improve health or as a bridge to other interventions, but further research is needed to fully understand their long-term implications.
